SCHEMBL25787809

SCHEMBL25787809

FC(P)OCCn1nnc(-c2ccccc2Nc2ccc(C(F)(P)P)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ MAPT P10636 1/20 0.35
▸ DDX3X O00571 1/20 0.35
▸ ABCG2 Q9UNQ0 8/20 0.35
▸ TAS2R14 Q9NYV8 1/20 0.34
▸ LMNA P02545 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ ABCB1 P08183 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ ATM Q13315 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ USP2 O75604 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25787720 0.87 KMT2A (0.42) SMN1; SMN2MAPTABCG2LMNAKMT2A
SCHEMBL20552901 0.86 ABCG2 (0.41) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL25787726 0.85 USP2 (0.43) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL25787758 0.84 SMN1; SMN2 (0.36) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL25787836 0.82 ABCG2 (0.41) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL20552459 0.80 ABCG2 (0.47) SMN1; SMN2MAPTDDX3XABCG2LMNA
SCHEMBL21749240 0.80 ABCG2 (0.43) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL20551929 0.78 USP2 (0.48) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL21749269 0.77 ABCG2 (0.46) SMN1; SMN2MAPTDDX3XABCG2TAS2R14
SCHEMBL20552626 0.77 ABCG2 (0.39) SMN1; SMN2MAPTDDX3XABCG2TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 SMN1; SMN2 3035/4885MAPT 516/4885DDX3X 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback